Sanofi

Digital Transformation Summit India Announces The Top 100 Digital Leaders In India

Retrieved on: 
Monday, November 20, 2023
Petro, Vodafone Idea Ltd, SAP, Associate, Essar Group, Alkem Laboratories, Digital Solutions, USV, Information technology, Brookfield Renewable Partners, EPL, High Street Phoenix, Unichem Laboratories, Information, Shared services, Security, Reliance Power, CEAT (company), Region, Information officer, Laboratory, Great Eastern Shipping, HDFC Life, AVP, Union Bank, HDFC, HDFC Bank, DT, BNP Paribas, Digital, Johnson & Johnson, SBI, IndiaFirst Life Insurance Company, RPG Group, Digital transformation, Lead, Welspun Group, DPO, Fitting, Investment, Corporation, Infrastructure, Sanofi, Camlin Fine Sciences, Restaurant Brands, Thermo Fisher Scientific, CIO, VVF, Axis Bank, Bajaj Electricals, CISO, Union Bank of India, Wellington School, ICICI Prudential Life Insurance, Management

MUMBAI, INDIA, Nov 20, 2023 - (ACN Newswire) - The Digital Transformation Summit, India, a premier event at the forefront of technological innovation, is thrilled to unveil DT 100, a prestigious initiative that recognises the remarkable achievements of technology leaders in India.

Key Points: 
  • MUMBAI, INDIA, Nov 20, 2023 - (ACN Newswire) - The Digital Transformation Summit, India, a premier event at the forefront of technological innovation, is thrilled to unveil DT 100, a prestigious initiative that recognises the remarkable achievements of technology leaders in India.
  • The DT 100 felicitation will take place at the Digital Transformation Summit in Mumbai on the 6th of December.
  • As we eagerly anticipate the Digital Transformation Summit, we extend our heartfelt congratulations to the 100 leaders who are paving the way for a digitally empowered future.
  • For more information about the Digital Transformation Summit India and the DT 100, please visit https://digitransformationsummit.com/india/

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

Retrieved on: 
Thursday, December 21, 2023
Lung cancer, Sanofi, Docetaxel, Glycoprotein, Research, Spacecraft, Apoptosis, Progression-free survival, CEACAM5, Incidence, Cell adhesion, Cancer, Neoplasm, IDMC, Patient, PFS, NSCLC, Vaccine

CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued

Key Points: 
  • CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued
    PARIS, December 21, 2023.
  • Sanofi is discontinuing the global clinical development program of tusamitamab ravtansine.
  • An Independent Data Monitoring Committee (IDMC) found that tusamitamab ravtansine as a monotherapy did not meet its dual primary endpoint of progression-free survival (PFS) compared to docetaxel.
  • “Our team is grateful to the patients, families and healthcare professionals involved in the tusamitamab ravtansine development program.

Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa

Retrieved on: 
Friday, December 15, 2023
Risk, Movement, Death, Climate change, Infection, World Health Organization, Drought, Democratic republic, HAT, CHMP, Neglected tropical diseases, Cattle, Development, European, Disease, Human, African trypanosomiasis, Animal, SDC, Parasitic disease, Climate, Tropical medicine, Developing country, Tecnologia, Aggression, EMA, WHO, Project, International health, Patient, Sanofi, Partnership, Trypanosomiasis, Research, Trypanosoma brucei, Psychosis, Clinical trial, Somatic symptom disorder, Committee, Zoonosis, Pharmaceutical industry

Sanofi, DNDi and the HAT-r-ACC consortium announce the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense).

Key Points: 
  • Sanofi, DNDi and the HAT-r-ACC consortium announce the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense).
  • rhodesiense sleeping sickness, an acute and lethal form of this parasitic disease found in Eastern and Southern Africa.
  • Sleeping sickness, or human African trypanosomiasis (HAT), is usually fatal without treatment.
  • Both forms of sleeping sickness are transmitted by the bite of infected tsetse flies, which are found in 36 African countries.

Press Release: Availability of the Q4 2023 Memorandum for modelling purposes

Retrieved on: 
Friday, December 15, 2023
Sanofi

Paris, France – December 15, 2023.

Key Points: 
  • Paris, France – December 15, 2023.
  • Sanofi announced today that its Q4 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website:
    As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results.
  • This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count.
  • Sanofi's fourth-quarter 2023 results will be published on February 1, 2024.

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

Retrieved on: 
Monday, December 11, 2023
Dexmedetomidine, Cardiology, Agitation, FDA, Roche, Actelion, Reata Pharmaceuticals, GSK, Pfizer, IND, Adamas, Medicine, Physician, University, Mount Sinai School, Schizophrenia, Doctor of Philosophy, MEK, Journal of Clinical Pathology, Intermittent explosive disorder, GSK plc, New product development, Caregiver, EMA, Therapy, Patient, Intelligence, Development, Senior, DSM-IV codes, Bipolar disorder, Sanofi, Royal college, Acquisition, Prostate cancer, Clinical trial, Biogen, Pharmaceutical industry

NEW HAVEN, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor appointment as part of the Company’s strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates.

Key Points: 
  • Vincent J. O’Neill, M.D., Senior Vice President and Chief Research & Development Officer of OnkosXcel Therapeutics, has been promoted to Executive Vice President, Chief of Product Development and Medical Officer of BioXcel Therapeutics.
  • Additionally, Rajiv Patni, M.D., has been appointed to the newly created position of Strategic Clinical Advisor to the BioXcel Therapeutics Chief Executive Officer and Board of Directors.
  • Prior to joining BioXcel Therapeutics, Dr. O’Neill held senior leadership roles at several leading global pharmaceutical companies, including Sanofi, Genentech, and GlaxoSmithKline.
  • “I look forward to working with the BioXcel leadership team in continuing to address the unmet medical needs of patients and caregivers and advance the Company’s product-development goals.”

Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics

Retrieved on: 
Monday, December 11, 2023
Heart, Maze, Patient, Hope, Sanofi, Partnership, Knowledge, FTC, Therapy, Pharmaceutical industry

Sanofi is disappointed with the Federal Trade Commission’s announcement that it is seeking a preliminary injunction against a proposed licensing agreement between Sanofi and Maze Therapeutics.

Key Points: 
  • Sanofi is disappointed with the Federal Trade Commission’s announcement that it is seeking a preliminary injunction against a proposed licensing agreement between Sanofi and Maze Therapeutics.
  • We respectfully disagree with the action by the FTC which also delays potential advancements that could impact the lives of patients.
  • The Maze partnership was designed to apply Sanofi’s resources, knowledge, and expertise to accelerate the development of MZE001, with the hope of addressing unmet medical needs for this devastating condition.
  • Sanofi remains committed to address the Pompe patient community’s unmet needs.

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi

Retrieved on: 
Thursday, December 7, 2023
Sanofi, HS, Inflammation, Disease, Doctor of Philosophy, Therapy, Oral medicine, International development, TPD, Patient, Safety, Pharmaceutical industry

WATERTOWN, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the first patient has been dosed in the randomized Phase 2 clinical trial (ADVANTA) evaluating KT-474 (SAR444656) in AD, generating a $15 million milestone payment under its collaboration with Sanofi. The Phase 2 study will evaluate the efficacy and safety of KT-474, a first-in-class, investigational IRAK4 degrader, compared with placebo in adult patients with moderate to severe AD. Sanofi is conducting Phase 2 KT-474 studies in both AD and HS, and dosed the first HS patient in October 2023, which generated a $40 million milestone payment under the terms of the collaboration. Study completion dates for both trials are projected in the first quarter of 2025.

Key Points: 
  • The Phase 2 study will evaluate the efficacy and safety of KT-474, a first-in-class, investigational IRAK4 degrader, compared with placebo in adult patients with moderate to severe AD.
  • Sanofi is conducting Phase 2 KT-474 studies in both AD and HS, and dosed the first HS patient in October 2023 , which generated a $40 million milestone payment under the terms of the collaboration.
  • Study completion dates for both trials are projected in the first quarter of 2025.
  • “We are pleased to be working with Kymera to explore the potential of IRAK4 degradation to treat a variety of inflammatory conditions, including in our recently initiated Phase 2 AD and HS trials.”

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

Retrieved on: 
Tuesday, December 5, 2023
Workforce, DR5, Sanofi, IND, Antibody, FDA, Colorectal cancer, FOLFIRI, CD20, SLE, IGM, Clinical trial, Rheumatoid arthritis, Inflammation, Investigational New Drug, Lupus, CD38, Bevacizumab, Myopathy, Myositis, Patient, Immunoglobulin M, Vaccine

In conjunction with this strategic refocusing, the Company will be reducing its workforce by approximately 22 percent.

Key Points: 
  • In conjunction with this strategic refocusing, the Company will be reducing its workforce by approximately 22 percent.
  • As a result of these actions, IGM expects to extend its cash runway into the second quarter of 2026.
  • “IGM continues to have a tremendous opportunity to transform a variety of disease areas using an entirely new class of antibody medicines,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.
  • As a part of this strategic refocusing, the Company will halt the following clinical development activities:

Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise

Retrieved on: 
Monday, December 4, 2023
Phase, Immune system, Infection, AstraZeneca, Executive Committee, Doctor of Philosophy, Novartis, Neoplasm, Celgene, M.D, Hematology, Patient, Bristol Myers Squibb, Sanofi, Bone marrow, Vaccine

Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise

Key Points: 
  • Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise
    PARIS, France, 04 December 2023 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T cell progenitor therapy platform to fully and rapidly re-arm the immune system against tumors and infection, today announces the appointment of Dr. Abderrahim (Rahim) Fandi as Chief Medical Officer, effective immediately.
  • Dr Fandi brings more than 25 years of experience of oncology clinical development programs in the pharmaceutical and biotechnology industry.
  • Prior to this, Rahim held senior clinical research and development positions at Celgene, Novartis, Bristol Myers Squibb and AstraZeneca.
  • Karine Rossignol, Chief Executive Officer of Smart Immune, said: “Rahim’s extensive experience in clinical development to explore new immuno-oncology technologies will be an invaluable asset to Smart Immune.

20Med Therapeutics Appoints Industry Veteran Hugo Fry as Chief Business Officer to Expedite mRNA Vaccine Delivery Platform Program

Retrieved on: 
Wednesday, November 29, 2023
Commercialization, LNP, Sanofi, London Business School, Drug discovery, Messenger, Nuclear power plant, CEPI, JPMorgan Chase, Therapy, Duke University, University, Market access, TouchLight, Regulatory affairs, PNP, Publication, Infection, Vaccine

Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer.

Key Points: 
  • Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer.
  • Hugo Fry has 29 years of leadership experience in the pharmaceutical and biotechnology industry across multiple business models, therapeutic areas, and companies, including Sanofi.
  • Hugo has a strong and recent track record of business development and licensing deals in the pharma and biotech sectors.
  • +++ Meet the 20Med Therapeutics team in San Francisco during the JPMorgan week, January 8-12, 2024 to discuss partnering opportunities around our PNP mRNA vaccine delivery platform +++